Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab for relapsed haematological malignancies post-alloSCT
NCT03146468Phase 2Unknown
- Sponsor
- Melbourne Health
- Start
- May 2017
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in haematological malignancy, sponsored by Melbourne Health. Status: unknown.
02
Drugs
03
Conditions
haematological malignancy
Beyond the preview
Go deeper on NCT03146468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146468.